CWM
BIB icon

Concert Wealth Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Concert Wealth Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,997
Closed -$271K – 703
2015
Q2 		$271K Buy
+2,997
New +$258K 0.04% 543

Other funds holding BIB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCAM
Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
AIG
American International Group New York $2.93M AUM 12.08% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
Wilbanks Smith & Thomas Asset Management
Wilbanks Smith & Thomas Asset Management Norfolk, Virginia $3.57B AUM 21.11% 1-Year Est. Return
BHA
Beech Hill Advisors New York $226M AUM 37.59% 1-Year Est. Return

Concert Wealth Management's BIB Position: Q3 2015 in Review

Concert Wealth Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2015, closing a stake of 2,997 shares — an estimated $271K sold.

Concert Wealth Management first reported a position in BIB in Q2 2015 and held it in 1 quarter. The position peaked at $271K in Q2 2015. 24 funds tracked by Wall St. Rank hold BIB as of Q3 2015.

  • Concert Wealth Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2015 after selling out during the quarter.
  • Concert Wealth Management sold 2,997 ProShares Ultra NASDAQ Biotechnology shares in Q3 2015, an estimated $271K.
  • Concert Wealth Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2015 and held it in 1 quarter.
  • Concert Wealth Management's ProShares Ultra NASDAQ Biotechnology position peaked at $271K in Q2 2015.
  • 24 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2015.

Based on Concert Wealth Management's 13F filing for Q3 2015, filed 2 Nov 2015.